Check-Cap Ltd. (NASDAQ:CHEK) Sees Significant Decrease in Short Interest

Check-Cap Ltd. (NASDAQ:CHEK) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 116,000 shares, a drop of 27.5% from the January 31st total of 159,900 shares. Approximately 2.7% of the shares of the stock are sold short. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Check-Cap in a report on Saturday. They set a “sell” rating on the stock.

Check-Cap Price Performance

Shares of Check-Cap stock traded up $0.01 during trading on Wednesday, hitting $0.80. The stock had a trading volume of 4,765 shares, compared to its average volume of 988,913. The business has a fifty day moving average of $1.09 and a two-hundred day moving average of $1.22. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.45. The firm has a market cap of $4.65 million, a P/E ratio of -0.27 and a beta of 0.16.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.